Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Nura Bio Raises $68M Series A, Total Funds Exceed $140M
Details : The financing will support the clinical development of NB-4746, a SARM1 inhibitor currently being evaluated in early-stage trials for the treatment of amyotrophic lateral sclerosis.
Brand Name : NB-4746
Molecule Type : Small molecule
Upfront Cash : Undisclosed
September 17, 2024
Nura Bio Initiates Phase I Clinical Trial for its Oral, Brain-Penetrant SARM1 Inhibitor, NB-4746
Details : NB-4746 is believed to be a first-in-class, oral, brain-penetrant, neuroprotective SARM1 inhibitor with broad therapeutic potential across diseases of the central, peripheral, and ocular nervous systems.
Brand Name : NB-4746
Molecule Type : Small molecule
Upfront Cash : Not Applicable
August 25, 2023
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Publication of research elucidating molecular details of conserved, NAD-dependent inhibitory mechanism that results in highly potent small molecule inhibitors of NAD hydrolases like SARM1 and CD38.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Nura Bio seeks to alter the course of neurological disease by targeting the fundamental pathways underlying axon degeneration and neuroimmune regulation to preserve neuronal integrity.
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Undisclosed
July 29, 2020
LOOKING FOR A SUPPLIER?